Lymphoma

CoVac-1, a COVID-19 vaccine, induced T-cell responses in patients with B-cell deficiencies, including those with lymphoma and leukemia, according to study results presented during American Association for Cancer Research Annual Meeting.

Natural killer cells combined with a bispecific antibody induced response among nearly 90% of patients with relapsed or refractory CD30-positive lymphoma, according to phase 1/phase 2 trial results.

Early phase 1 trial results using an investigational chimeric antigen receptor T-cell therapy manufactured at University of Colorado show encouraging efficacy for adults with relapsed or refractory B-cell non-Hodgkin lymphoma.

The FDA approved axicabtagene ciloleucel as second-line treatment for adults with large B-cell lymphoma who are refractory to first-line chemoimmunotherapy or experienced disease relapse within 12 months of initial treatment.

B-cell activating factor is a ligand protein, which makes it uniquely suited as a therapeutic option for the newly emerging class of multitargeted chimeric antigen receptor T-cell therapies.

Early intrathecal therapy effectively resolved symptoms related to high-grade neurotoxicity among patients who received chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma, according to a research letter in JAMA Oncology.

Adding romidepsin to busulfan and fludarabine reduced incidence of relapse among patients receiving allogeneic stem cell transplant for aggressive T-cell malignancies, according to results of a phase 1/phase 2 study.

Researchers have developed a novel quantitative assay that can predict which patients will achieve durable remissions after CD19-directed chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma.

Amit Maity, MD, PhD, has been appointed chair of the department of radiation oncology for Spencer Fox Eccles School of Medicine at University of Utah.

ASH announced the 36 recipients of the society’s 2022 Scholar Awards.